Current News

Idev Supera® Stent Data Published in Journal of Endovascular Therapy

Idev Technologies, a PEI principal supplier, recently announced that 24-month data on its Supera® Veritas stent has been published in December’s issue of the Journal of Endovascular Therapy - a milestone for the technology.

Included in the data are the results of the Leipzig Supera Registry, which studied the use of the stent in patients with peripheral artery disease of the superficial femoral artery (SFA).

The single-centre registry is a retrospective analysis of 107 patients with atherosclerotic femoropopliteal lesions. These lesions were of varying complexities, such as those with total occlusions and heavily calcified lesions.

All patients were treated with the Supera stent, and were followed for up to two years by Doppler ultrasound, radiographic stent examination, and clinical assessments of Rutherford Becker class and ankle brachial index (ABI).

Corresponding author of the study, Dierk Scheinert, MD, commented:

“The results of our analysis showed a 99 percent procedural success, with a primary patency at 12 months of 85 percent and at 24 months of 76 percent. Importantly, follow-up radiographs revealed no stent fractures, and clinical assessments of Rutherford-Becker class and ABI were all statistically significantly improved at all follow-up intervals.”

The Supera stent is CE marked for biliary and peripheral vascular use in Europe, Canada, Australia and several Asia-Pacific regions. In the United States, the Supera stent is cleared for binary use, and is currently being studied in an ongoing FDA-approved IDE trial for treatment of peripheral artery disease of the SFA.


For more information on the Idev Supera stent please contact your local hospital representative. Alternatively, call PEI directly on +353 1 419 6900.

August 2019
MTWTFSS
29 30 31 1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31 1
2 3 4 5 6 7 8

Related Links